Endocrine Abstracts

Background: The SCOUT trial showed that sibutramine produced weight loss with some increased cardiovascular morbidity but not mortality. But these results should not be extrapolated to a routine practice as a lot of the SCOUT participants had contraindications for sibutramine. In order to summarise data on efficacy and safety of sibutramine administration in routine clinical practice according to approved indications and to implement risks monitoring system in Russia, PRIMAVER...